Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

Stay updated with the latest breakthroughs in endometrial cancer treatment in this MEDtalk, when Professor Shannon Westin sheds light on promising results presented at ESMO 2023, including the addition of atezolizumab to chemotherapy for patients with recurrent or advanced-stage endometrial cancer; intriguing response data around the drug tisotumab vedotin in combination with immuno-oncology agents and chemotherapy; and insights into molecular data from the RUBY trial, which looked at dostarlimab with chemotherapy, and the GY018 study, which examined pembrolizumab in chemotherapy.